Should a doctor prescribe hormone replacement therapy which has been manufactured from mare's urine?

Journal of Medical Ethics

Volumn 22, Issue 4, 1996, Pages 199-203

  Cox, Dennis ^a,b  

^a Spinney Surgery   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Ethics; HRT

Indexed keywords

CONJUGATED ESTROGEN;

ANIMAL WELFARE; DRUG CHOICE; DRUG MANUFACTURE; HORMONE SUBSTITUTION; HORSE; HUMAN; MEDICAL ETHICS; PATIENT SATISFACTION; PRESCRIPTION; REVIEW;

EID: 0029737113     PISSN: 03066800     EISSN: None     Source Type: Journal    
DOI: 10.1136/jme.22.4.199     Document Type: Review

References (18)

1. Ryan S. Horses suffer for menopausal pill. The Sunday Times 1994 Dec 4: 1 (cols 1-6).
2. Personal communication from Miss JS Robertson. Medical Information Department, Wyeth. 1995 Dec 11.
3. Dawkins M. The scientific basis for assessing suffering in animals. In: Singer P, ed. In defence of animals. Oxford: Blackwell, 1985: 27-40.
4. Anonymous. People for ethical treatment of animals. Animal Times. 1994; Jul/Aug: 14-5.
5. Jones D. The bitter pill which is hard to swallow. Today 1995 Jan 16: 19 (cols 1-3)
6. Singer P. Practical ethics [2nd ed]. Cambridge: Cambridge University Press, 1993: 89.
7. Ryder R. Speciesism in the laboratory. Dawkins M. The scientific basis for assessing suffering in animals. See reference 3: 77-88.
8. Singer P, ed. Applied ethics. Oxford Readings In Philosophy Oxford: Oxford University Press, 1986: 221.
9. Singer P. Practical ethics [2nd ed]. Cambridge: Cambridge University Press, 1993: 57-67.
10. Nabulsi AA, et al. New England Journal of Medicine 1993; 328: 1069-75.
11. Whittaker PG, et al. Lancet 1980: 1 (8158): 14-6.
12. Marslew U, Overgaard K, Riis B, Christiansen C. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms and bleeding. Obstetrics and Gynaecology, 1992; 79: 302-10.
13. Haarbo J, Hassager C, Jensen B, Riis B, Christiansen C. Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives. American Journal of Medicine. 1991 90: 584-9.
14. Findings of a consensus meeting in 1987, sponsored by the European Foundation for Osteoporosis and Bone Disease.
15. Marslew U, Overgaard K, Riis B, Christiansen C. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms and bleeding. Obstetrics and Gynaecology. 1992; 79: 302-10.
16. Holland E, Leather A, Studd J, Garnett T. The effect of a new sequential oestradiol valerate and levonorgestrel preparation on the bone mineral density of postmenopausal women. British Journal of Obstetrics and Gynaecology 1993; 100: 966-7.
17. British National Formulary 1995; 30: 301. Joint publication of the British Medical Association and the Royal Pharmaceutical Society of Great Britain.
18. Re F (mental patient sterilisation) [1989] 2 All ER 545 (HL).